Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Data set up approval of what would be second gene editing medicine

https://www.statnews.com/2026/04/27/intellia-therapeutics-phase-3-trial-hereditary-angioedema-crispr-treatment/ By Jason MastApril 27, 2026 General Assignment Reporter